CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
29,000
Stocks News & Analysis
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.50 | 15.50 | -0.17% |
| CAC 40 | 7,827.63 | 5.25 | -0.07% |
| DAX 40 | 25,259.90 | 17.78 | -0.07% |
| Dow JONES (US) | 51,716.69 | 133.86 | -0.26% |
| FTSE 100 | 10,650.33 | 5.95 | -0.06% |
| HKSE | 24,345.22 | 74.02 | 0.30% |
| NASDAQ | 27,185.11 | 60.80 | -0.22% |
| Nikkei 225 | 67,777.52 | 1,253.40 | -1.82% |
| NZX 50 Index | 13,749.60 | 78.02 | -0.56% |
| S&P 500 | 7,803.32 | 3.92 | -0.05% |
| S&P/ASX 200 | 8,783.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,800.86 | 3.62 | 0.10% |